Mereo BioPharma Group plc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
MREO$0.30+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(43,253) | $(29,466) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation | 7,390 | 4,924 |
| Depreciation | 143 | 171 |
| Amortization of intangible assets | 438 | 395 |
| Amortization of operating lease right-of-use assets | 507 | 495 |
| Change in fair value of warrants | 419 | (245) |
| Interest income | — | (102) |
| Interest expense | 1,351 | 1,942 |
| Foreign currency transaction (gain)/loss | (1,210) | 2,347 |
| Non-cash consideration, milestone payment | 1,750 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2,980 | 502 |
| Research and development incentives receivable | (1,649) | 456 |
| Accounts payable | 146 | (1,263) |
| Accrued expenses and other liabilities | (1,192) | (710) |
| Operating lease liabilities | (654) | (578) |
| Net cash used in operating activities | (32,834) | (21,132) |
| Cash flows from investing activities | ||
| Purchase of intangible assets | (699) | (419) |
| Net cash used in investing activities | (699) | (419) |
| Cash flows from financing activities | ||
| Proceeds from financing agreement with TAP | — | 100 |
| Proceeds from issuance of ordinary shares | 47,000 | 11,605 |
| Transaction costs on issuance of ordinary shares | (853) | (511) |
| Transaction costs on convertible loan notes | — | (33) |
| Redemption of convertible loan notes | — | (3,188) |
| Net cash provided by financing activities | 46,147 | 7,973 |
| Effect of exchange rate changes | (233) | 2,818 |
| Increase/(decrease) in cash and cash equivalents | 12,381 | (10,761) |
| Cash and cash equivalents at January 1, | 57,421 | 68,182 |
| Cash and cash equivalents at December 31, | $69,802 | $57,421 |
| Supplemental disclosure | ||
| Cash paid for interest | 21 | 884 |
| Cash paid/(received) for income taxes | — | (1,337) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.